<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C6DFF67B-2689-4DDB-B53F-246E2592DE6D"><gtr:id>C6DFF67B-2689-4DDB-B53F-246E2592DE6D</gtr:id><gtr:name>Research Center for Animal Health</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C6DFF67B-2689-4DDB-B53F-246E2592DE6D"><gtr:id>C6DFF67B-2689-4DDB-B53F-246E2592DE6D</gtr:id><gtr:name>Research Center for Animal Health</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/94A52DDD-9B28-4E2D-A0AB-B0DC2A9EB4D3"><gtr:id>94A52DDD-9B28-4E2D-A0AB-B0DC2A9EB4D3</gtr:id><gtr:firstName>Emmanuel</gtr:firstName><gtr:otherNames>A</gtr:otherNames><gtr:surname>Asante</gtr:surname><gtr:orcidId>0000-0003-3771-4843</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U123160653"><gtr:id>14214C1F-5E55-4438-86E4-C33E4898BF8A</gtr:id><gtr:title>Transgenic Modelling of Human Prion Susceptibility and Diseases</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U123160653</gtr:grantReference><gtr:abstractText>While the Unit is working to find alternatives to the use of laboratory animals in our research, at this time some crucial work can only be done in mice. We have developed a key series of animal models of human prion disease. This involves introducing various forms of the human prion protein gene into mice so that they produce human protein. This includes both the M and the V form, as well as various genetic mutations that are seen in patients with inherited forms of prion disease (also known as familial CJD and GSS). Such mice are very sensitive to infection with CJD prions and have allowed us to study the various strains of human prions, including notably the strain which causes variant CJD. These studies have formed an important part of the evidence showing that variant CJD is the human counterpart of BSE and we have been able to reproduce the characteristic features of variant CJD seen down the microscope (known as florid plaques) in these mice. This model then allows us to test possible treatments for the human disease. Another key area of this research is to understand the so-called species barrier that limits the ability of prions from one species of animal to infect another. The most important of these barriers for us to study is that between cows and humans, but obviously we cannot study this directly by infecting humans so instead we use these special mice (known as transgenic mice) in which we have placed a human prion protein gene in order to estimate how large this barrier may be and to begin to understand how the barrier works. We are also studying some of the inherited prion diseases using mice. By putting the mutant human gene in mice, we can study how it causes disease in those families with a faulty prion protein gene.</gtr:abstractText><gtr:technicalSummary>In studies now spanning well over a decade we have developed highly specialised transgenic transmission facilities for comprehensive studies of human prion disease under appropriate biocontainment. Species-barrier-free transmission of many forms of human prion disease is available. While excellent, well characterised models are now in routine use, further improvement to these models, and the development of improved models for the assay of vCJD prions are underway. In addition to ongoing basic research into intermammalian and strain-specific transmission barriers and characterisation of the prion strains causing human disease, this facility is being applied to address key public health issues which require human prion bioassay (tissue distribution of infectivity and human prion decontamination for example) and to study putative prion therapeutics. Animal models of a range of inherited human prion diseases are being studied, in particular to determine if prions are produced spontaneously in such animals. The specific aims of this programme are as follows:- To establish the full range of prion strains causing human disease and to attempt to biologically clone these for biochemical study (with programme 6) - To complete our long-term characterisation of intermammalian prion transmission barriers of relevance to public health and to understand the interaction between prion strain diversity and these barriers - To model the human inherited prion diseases and determine whether prions can be generated spontaneously in these models - To generate new transgenic lines as required to model novel human PrP polymorphisms and candidate prion modifier genes (in conjunction with programmes 1 and 2) - To generate transgenic models of frontotemporal dementia (in conjunction with programme 10) - Development and use of standardised models for evaluation of candidate therapeutics - To continue to provide and update the Units Transgenic Core facility and support animal research throughout the Unit</gtr:technicalSummary><gtr:fund><gtr:end>2017-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1999-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>13943838</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Research Center for Animal Health</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Collaborating with Spanish Lab on the animal modelling of BSE and vCJD in transgenic mice</gtr:description><gtr:id>B04963E7-6372-490F-ADB6-3494482DD313</gtr:id><gtr:impact>For the moment, this is a one-off collaboration. A manuscript &amp;quot;Val129-PrP is a strong molecular protector against BSE zoonotic transmission but fails to prevent human-to-human vCJD transmission&amp;quot; resulting from this collaboration is under second review at Emerging Infectious Diseases.</gtr:impact><gtr:outcomeId>58aeba72830a83.69720197-1</gtr:outcomeId><gtr:partnerContribution>At this stage only I have contributed to Dr Torres' project, but there remains a good change for reciprocation in the near future, since we are both internationally prominent for transgenic modelling of prion diseases.</gtr:partnerContribution><gtr:piContribution>I provided intellectual input and crucial control reference samples to Dr Juan Maria Torres; Research Center for Animal Health (CISA-INIA), Spain. This collaboration came about after I listened to Dr Torres' talk at an International Prion conference in Japan in May 2016 where I drew his attention to an important result that he did not highlight as much as it ought to be. He admitted that he was unsure of the interpretation which I duly obliged and explained. He agreed to confirm my idea if I would send him reference samples from my own work done previously. This collaboration has been successful and a manuscript coming out of this work has just been revised and sent back to Emerging Infectious Diseases for publication, with me as a co-author. I contributed significantly to the manuscript writing and polishing because I have already published extensively on the subject of modelling BSE and vCJD infection in transgenic mice expressing human prion protein. I was also able to help with the English grammar and sentence constructions, as the only UK scientist on the authors list.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Invited Speaker -Leonard Wolfson Experimental Neurology Centre Annual Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BDB91C49-39A4-40DB-B599-186A1DA7DC08</gtr:id><gtr:impact>I was invited to speak for 20 minutes followed by questions and answers session at the UCL Leonard Wolfson Experimental Neurology Centre Annual Symposium. My given topic was &amp;quot;Natural genetic variation gives complete resistance in prion diseases&amp;quot;. This lecture gave me the chance to disseminate my work published in high impact Nature magazine a few months previously. This was an all-day symposium (1000-1730) on 2nd March 2016 involving 11 other invited speakers, that was attended by patient groups for Alzheimer's and other neurodegenerative diseases.</gtr:impact><gtr:outcomeId>58aeb261e50e40.48996927</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecturing Final Year Students</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1CC1D717-8E52-4EED-B006-0CFDBCCFCB23</gtr:id><gtr:impact>Two x 1-hour lectures each on Clinical and Research aspects of Prion Diseases to 65 Final Year BSc Neuropharmacology and Neurotoxicology students at Kings and Guys Hospital Medical School, London. Set exam questions and provide model answers to.

Asked to set examination questions after the lecture.</gtr:impact><gtr:outcomeId>70D9536C020</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecturing on Prion Diseases to Virologists</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>03065A28-B715-457B-9655-60B8337DB0F6</gtr:id><gtr:impact>1 hour Lecture on Human Prion Diseases to workshop attendees of &amp;quot;Virology Course Update&amp;quot; at St. Thomas' Hospital, London.

All attendees would be accredited for their professional development</gtr:impact><gtr:outcomeId>2B2AC0F3C4F</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture to staff of Zenith Bank (Accra, Ghana)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>40CB28EB-88FC-429E-A785-74952B39E349</gtr:id><gtr:impact>I gave a lecture on &amp;quot;A brief introduction to genetic engineering&amp;quot; to 40 staff of Zenith Bank in Ghana, early morning before Bank opened to the public at 0800.

Those with science background, including the manager, asked a lot of relevant questions. They expect a lecture on a different topic when I next visit the country.</gtr:impact><gtr:outcomeId>dQoMN5GdCBG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecturing to PhD and MPhil Students at the Unversity of Ghana</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C8EE8CBA-9BE6-4175-BF54-A1A3047F066B</gtr:id><gtr:impact>I gave 3 lectures totalling 6 hours to PhD and MPhil students at the University of Ghana, Department of Molecular and Cell Biology of Infectious Pathogens in November 2016.
These were formal lectures on prions as and alternative infectious pathogen to commonly know viruses and bacterial, recombinant DNA technology and CRISPR/Cas genome editing technology. I have now been asked to lecture regularly at this department in April and November of each year.</gtr:impact><gtr:outcomeId>58aead85c95c02.75763021</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture on prion disease modelling</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8378CAF4-979E-4A09-B28C-8B0742C16DB4</gtr:id><gtr:impact>Researchers, Lecturers and PhD students at Royal Veterinary College, attended my lunchtime lecture at their Hawkshead site which was simultaneously broadcast via video link to the RVC Camden Town site for similar audience to join in.

n/a</gtr:impact><gtr:outcomeId>iKvsTQNoGdr</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture on genetics to a Lay Audience</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A62DCEB0-0769-44AE-BE64-5397C76D08A8</gtr:id><gtr:impact>Invited to lecture on Basic Human Genetics and Sickle Cell Anaemia to 25x Zenith Bank Staff in Ghana during my holidays.

Many in the audience with science background asked pertinent questions especially on sickle cell anaemia which commonly affects peope of African descent.</gtr:impact><gtr:outcomeId>jRpt4xp7Qyd</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk on Basic Genetics to a youth group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F581D487-62F7-49A9-94CB-CF3CED408C18</gtr:id><gtr:impact>Invited to talk on Basic Genetics and its application to sickle cell anaemia to non-scientists.

Had very positive feedback after the talk</gtr:impact><gtr:outcomeId>0652520469F</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture at Unversity of Ghana, Department of Cell and Molecular Biology of Infectious Pathogens</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>65007471-DF3F-4DEF-9CA4-26B79939E58A</gtr:id><gtr:impact>Lecture entitled &amp;quot;A single amino acid change completely switches off a lethal dementia in a brain-eating tribe&amp;quot;. More than 100 in the audience with some standing. Presentation was followed with 30 minutes of questions and answers, and led to invitation to act as a visiting lecturer for the Department in the University of Ghana.</gtr:impact><gtr:outcomeId>56bdccd73f5a77.12631293</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Heterozygosity at PRNP polymorphic residue 127 (G127V) is predicted to have offered protection against a form of prion disease called kuru. New transgenic lines have been made expressing polymorphic Valine-127 that are resistant to all human prions. These mice are being used to study the mechanism by which heterozygosity at amino acid position 127 offered protection against kuru. As characterisation is not completed (for instance susceptible to animal prions is being investigated) these mice have not been offerred to other researcher as yet.</gtr:description><gtr:id>D8FE9F9D-72D2-4455-BC20-0CF006280A8D</gtr:id><gtr:impact>The new transgenic mice offer a way of investigating how a single amino acid change in PRNP is able to confer an absolute barrier against prion disease. These new transgenic mice need further characterisation but have already yielded some new and interesting unpublished data.</gtr:impact><gtr:outcomeId>Cto96ZmkH4M</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>New transgenic line-G127V for kuru modelling</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AA9746E6-C3E3-4556-A3D9-69187A05567B</gtr:id><gtr:title>Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25db88fcbd041997bffe5354e9a3b87e"><gtr:id>25db88fcbd041997bffe5354e9a3b87e</gtr:id><gtr:otherNames>Wadsworth JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>14798403D54</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C40B50C9-615C-4A96-95DC-757F44A5EEF4</gtr:id><gtr:title>Review: contribution of transgenic models to understanding human prion disease.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25db88fcbd041997bffe5354e9a3b87e"><gtr:id>25db88fcbd041997bffe5354e9a3b87e</gtr:id><gtr:otherNames>Wadsworth JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>ij4iuL6xaR1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60FADDDD-65FB-408F-9774-6273320DBE19</gtr:id><gtr:title>Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d33325db7c1bbd99fe8b86ca728e230"><gtr:id>6d33325db7c1bbd99fe8b86ca728e230</gtr:id><gtr:otherNames>Asante EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>93D60814CF9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58C6C039-CFB9-41AE-A29F-36814087DBA7</gtr:id><gtr:title>Rskalpha-actin/hIGF-1 transgenic mice with increased IGF-I in skeletal muscle and blood: impact on regeneration, denervation and muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Growth hormone &amp; IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b41f2ec7d605aedbebfd7f22396f4f92"><gtr:id>b41f2ec7d605aedbebfd7f22396f4f92</gtr:id><gtr:otherNames>Shavlakadze T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1096-6374</gtr:issn><gtr:outcomeId>B2C3BE568ED</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A795F423-2D4D-46F1-B999-626AD68EE14E</gtr:id><gtr:title>Overexpression of the Hspa13 (Stch) gene reduces prion disease incubation time in mice.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e86547207e717145b8a8421a11f93161"><gtr:id>e86547207e717145b8a8421a11f93161</gtr:id><gtr:otherNames>Grizenkova J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_13415_25_22869728</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E320446A-8B69-4190-86EC-50FC35712339</gtr:id><gtr:title>Protective Effect of Val-PrP against Bovine Spongiform Encephalopathy but not Variant Creutzfeldt-Jakob Disease.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f02a5fa81dcfbe42c9e58d7a5b836f27"><gtr:id>f02a5fa81dcfbe42c9e58d7a5b836f27</gtr:id><gtr:otherNames>Fern?ndez-Borges N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>5a8c2ceab27370.43460778</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A43FC0A-D30C-4499-91BC-B7B88CDB2B17</gtr:id><gtr:title>Inherited prion disease A117V is not simply a proteinopathy but produces prions transmissible to transgenic mice expressing homologous prion protein.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d33325db7c1bbd99fe8b86ca728e230"><gtr:id>6d33325db7c1bbd99fe8b86ca728e230</gtr:id><gtr:otherNames>Asante EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_13415_25_24086135</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56377CBD-AA9C-4B8A-B57E-5781A16DED23</gtr:id><gtr:title>Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/738fdd28790b74d120b2b7e362223ce0"><gtr:id>738fdd28790b74d120b2b7e362223ce0</gtr:id><gtr:otherNames>Ghazi-Noori S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_13415_25_22366797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E1F5905-FFE3-48C2-A60A-C428B8D28BC9</gtr:id><gtr:title>Review. The origin of the prion agent of kuru: molecular and biological strain typing.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25db88fcbd041997bffe5354e9a3b87e"><gtr:id>25db88fcbd041997bffe5354e9a3b87e</gtr:id><gtr:otherNames>Wadsworth JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>0D27FADE32F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>080CCAF7-FAB0-4909-AA3E-9D4ED324A726</gtr:id><gtr:title>Threshold for epileptiform activity is elevated in prion knockout mice.</gtr:title><gtr:parentPublicationTitle>Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5052a4ec1bbf8e1f6c3179c4f733ccd6"><gtr:id>5052a4ec1bbf8e1f6c3179c4f733ccd6</gtr:id><gtr:otherNames>Ratt? S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0306-4522</gtr:issn><gtr:outcomeId>PCU18VM8ktf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDBEBF21-2AEC-4592-8F7D-FF471F104628</gtr:id><gtr:title>Experimental sheep BSE prions generate the vCJD phenotype when serially passaged in transgenic mice expressing human prion protein.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c6b0f825cf34f269514039fa9fcb879"><gtr:id>2c6b0f825cf34f269514039fa9fcb879</gtr:id><gtr:otherNames>Joiner S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>5a8c2ceae7d4c2.33151620</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>484FE005-B892-4B9B-A259-C06CFAAA6FDB</gtr:id><gtr:title>Prion infectivity in variant Creutzfeldt-Jakob disease rectum.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25db88fcbd041997bffe5354e9a3b87e"><gtr:id>25db88fcbd041997bffe5354e9a3b87e</gtr:id><gtr:otherNames>Wadsworth JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>DD7524D205F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3ED7705-A873-4FA9-92DE-6E19A6933340</gtr:id><gtr:title>Chronic wasting disease prions are not transmissible to transgenic mice overexpressing human prion protein.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c101120111e9f19df81b4f0bdae6dff"><gtr:id>8c101120111e9f19df81b4f0bdae6dff</gtr:id><gtr:otherNames>Sandberg MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>ApZgN7fCxDX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15ECBE1E-E8DD-4B55-85A8-183D0AD84C56</gtr:id><gtr:title>Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d33325db7c1bbd99fe8b86ca728e230"><gtr:id>6d33325db7c1bbd99fe8b86ca728e230</gtr:id><gtr:otherNames>Asante EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>28A64335305</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD105DD2-C717-4422-A12F-9C0A9C5D2F39</gtr:id><gtr:title>Transmission Properties of Human PrP 102L Prions Challenge the Relevance of Mouse Models of GSS.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d33325db7c1bbd99fe8b86ca728e230"><gtr:id>6d33325db7c1bbd99fe8b86ca728e230</gtr:id><gtr:otherNames>Asante EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>56bdc4ee3d1ae0.52335677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB0277ED-C61E-4A61-9DE7-7E77A82D9F23</gtr:id><gtr:title>Effect of fixation on brain and lymphoreticular vCJD prions and bioassay of key positive specimens from a retrospective vCJD prevalence study.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25db88fcbd041997bffe5354e9a3b87e"><gtr:id>25db88fcbd041997bffe5354e9a3b87e</gtr:id><gtr:otherNames>Wadsworth JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>LiqWnCJ9kXV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>629660E7-3037-4769-B7C6-8A689ADEEB9B</gtr:id><gtr:title>Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25db88fcbd041997bffe5354e9a3b87e"><gtr:id>25db88fcbd041997bffe5354e9a3b87e</gtr:id><gtr:otherNames>Wadsworth JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>14CD5629504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4AC0944-299B-4236-A9D5-83BA70DC9DD4</gtr:id><gtr:title>Atypical scrapie prions from sheep and lack of disease in transgenic mice overexpressing human prion protein.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25db88fcbd041997bffe5354e9a3b87e"><gtr:id>25db88fcbd041997bffe5354e9a3b87e</gtr:id><gtr:otherNames>Wadsworth JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>doi_13415_911_121341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9738DD1-1BC0-40FD-A3F9-A247920C3461</gtr:id><gtr:title>A naturally occurring variant of the human prion protein completely prevents prion disease.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d33325db7c1bbd99fe8b86ca728e230"><gtr:id>6d33325db7c1bbd99fe8b86ca728e230</gtr:id><gtr:otherNames>Asante EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>56bdc4ee66c735.31382737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC0F938F-EE05-4D1D-AAB1-543D811A6A05</gtr:id><gtr:title>Interaction between prion protein and toxic amyloid ? assemblies can be therapeutically targeted at multiple sites.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f87882018fcf76fd424390a5a57f6bed"><gtr:id>f87882018fcf76fd424390a5a57f6bed</gtr:id><gtr:otherNames>Freir DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>ckr9MeJ4mGw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1DE0246-7644-4C14-95FA-9C28F5A2DD8E</gtr:id><gtr:title>Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d371ed1fef27a7d68529eead82f76ad7"><gtr:id>d371ed1fef27a7d68529eead82f76ad7</gtr:id><gtr:otherNames>Clayton EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>56bdc4ee13a9e9.38190049</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U123160653</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>